Protection against Multiple Subtypes of Influenza Viruses by Virus-Like Particle Vaccines Based on a Hemagglutinin Conserved Epitope

Table 3

IgG1 and IgG2a antibody responses against LAH-HBc in mice induced by intranasal (i.n.) administration of LAH-HBc with or without CTB^*a.

Group	Immunogen	Immunization route	Dosage (μg)	Serum Ab responses (ELISA, 2^n)
				IgG1	IgG2a	IgG2a/IgG1
A	LAH-HBc + CTB^*	i.n.	25	11.00 ± 1.00	12.00 ± 1.00	2
B	LAH-HBc	i.n.	25	11.00 ± 1.15	13.00 ± 1.58	4
C	LAH-HBc + CTB^*	i.n.	5	9.33 ± 1.48	9.33 ± 1.04	1
D	LAH-HBc	i.n.	5	7.00 ± 0	8.67 ± 1.07	3.18
E	LAH-HBc + CTB^*	i.n.	1	7.00 ± 0	7.67 ± 1.15	1.59
F	LAH-HBc	i.n.	1	6.33 ± 0.58	7.33 ± 0.58	1.99
G	CTB^*	i.n.	—	Undetected	Undetected	—
H	Control	i.n.	—	—	—	—

Mice were immunized with LAH-HBc vaccine as described in Table 1. The serum samples were examined by ELISA for specific IgG1 and IgG2a, respectively.
Results are expressed as means ± SD of tested mice in each group.